By developing an improved health data management system, the Virus Outbreak Data Network (VODAN)-Africa research team is enabling local and global distributed access to crucial data required to fight the COVID-19 pandemic, future disease outbreaks and general disease conditions.
Led by Professor Mirjam van Reisen of the Leiden University Medical Center (LUMC), VODAN-Africa is a project focused on addressing various issues that are common to health data management across the African continent. “Major challenges we are currently tackling include the deficiency in production of quality clinical data, lack of ownership of health data – especially when it is sent to foreign-based systems, as well as technical obstacles related to digitalization of data and regulatory differences across regions”, says Dr. Jeremia Pyuza, LUMC Global PhD student of the LUMC Departments of Parasitology and Pathology.
The Janssen-Cilag International N.V COVID-19 vaccine has received authorization for emergency use by the European Medicines Agency (EMA) on March 11. Developed with fundamental support from the Molecular Virology group of the Leiden University Medical Centre (LUMC), it is the fourth vaccine to be administered in the European Union. The Netherlands has ordered more than 11 million vaccine doses.
For many students from the LUMC’s academic programmes, studying abroad is an indispensable experience. Doing part of your studies abroad is a special experience, not only because of the sense of adventure of being abroad, also to develop a broader perspective on Life Sciences & Health, a highly international field. So, you can imagine the LUMC’s International Office’s struggle to have to tell students ‘no’ for a study experience abroad in the midst of the corona pandemic. In addition, the many lockdowns worldwide increased the workload dramatically for the International Office. Evelien Hack, Head of the International Office and Sandra van Deursen, senior administrative assistant, share how corona has impacted studying abroad.
The Leiden University Medical Center (LUMC) and Ixaka Ltd. have announced a research collaboration on 30 March 2021, to better understand REX-001, Ixaka’s lead cell therapy product. The project will be led by Professor Paul Quax, Head of Experimental Vascular Surgery at the LUMC, to support accelerated development of REX-001 in Phase III clinical trials for the treatment of chronic limb-threatening ischemia (CLTI).